For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the introduction of Tafamidis and Attruby represents a true advancement . These groundbreaking therapies preserve the transthyretin protein, preventing its destructive build-up and lessening the